Claims for Patent: 7,901,666

Summary for Patent: 7,901,666

Title:	Nanoparticles for protein drug delivery
Abstract:	The invention discloses a pharmaceutical composition for treating a subject comprising two or more bioactive nanoparticles, thus treating the subject by co-administering the bioactive nanoparticles to the subject, wherein a first and a second bioactive nanoparticles comprise a shell portion that is dominated by positively charged chitosan, a core portion that contains negatively charged substrate, and at least a first bioactive agent in the first nanoparticle and a second bioactive agent in the second nanoparticle.
Inventor(s):	Sung; Hsing-Wen (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee:	GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW)
Application Number:	12/455,339
Patent Claims:	1. A pharmaceutical composition for treating a subject comprising two or more bioactive nanoparticles, thus treating the subject by co-administering said two or more bioactive nanoparticles to said subject, wherein a first bioactive nanoparticle comprises a shell portion that is dominated by a first positively charged chitosan, a core portion that consists of a first negatively charged substrate, the first positively charged chitosan, and at least a zero-charge first compound, and wherein a second bioactive nanoparticle comprises a shell portion that is dominated by a second positively charged chitosan, a core portion that contains a second negatively charged substrate, the second positively charged chitosan, and at least a second compound. 2. The pharmaceutical composition of claim 1, wherein the first and second nanoparticles are loaded in capsules. 3. The pharmaceutical composition of claim 2, wherein said capsules are treated with an enteric coating. 4. The pharmaceutical composition of claim 2, wherein said capsules further comprise at least a solubilizer or pharmacopoeial excipients. 5. The pharmaceutical composition of claim 2, wherein said capsules further comprise a permeation enhancer. 6. The pharmaceutical composition of claim 5, wherein said permeation enhancer is selected from the group consisting of Ca.sup.2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives. 7. The pharmaceutical composition of claim 1, wherein the first nanoparticle is loaded in a first capsule and the second nanoparticle is loaded in a second capsule for co-administration to said subject. 8. The pharmaceutical composition of claim 7, wherein said first capsule or said second capsule is treated with an enteric coating. 9. The pharmaceutical composition of claim 7, wherein said first capsule or said second capsule further comprises at least a solubilizer or pharmacopoeial excipients. 10. The pharmaceutical composition of claim 7, wherein said first capsule or said second capsule further comprises a permeation enhancer. 11. The pharmaceutical composition of claim 10, wherein said permeation enhancer is selected from the group consisting of Ca.sup.2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives. 12. The pharmaceutical composition of claim 1, wherein the first or second chitosan comprises N-trimethyl chitosan, EDTA-chitosan, or chitosan derivatives. 13. The pharmaceutical composition of claim 1, wherein said first and second nanoparticles are loaded in tablets or pills. 14. The pharmaceutical composition of claim 1, wherein said first and second nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form. 15. The pharmaceutical composition of claim 1, wherein said second compound further comprises magnesium sulfate or TPP. 16. The pharmaceutical composition of claim 1, wherein the second compound comprises at least one non-insulin anti-diabetic drug. 17. The pharmaceutical composition of claim 16, wherein said non-insulin anti-diabetic drug is selected from the group consisting of insulin sensitizers, insulin secretagogues, GLP-1 analogs, and DPP-4 inhibitors. 18. The pharmaceutical composition of claim 16, wherein said non-insulin anti-diabetic drug comprises liraglutide, exenatide, albiglutide, or taspoglutide. 19. The pharmaceutical composition of claim 16, wherein said non-insulin anti-diabetic drug is selected from the group consisting of alpha-glucosidase inhibitors, amylin analog, sodium-glucose co-transporter type 2 (SGLT2) inhibitors, benfluorex, and tolrestat. 20. The pharmaceutical composition of claim 1, wherein the first or second compound is insulin or an insulin analog.

Details for Patent 7,901,666

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014		2025-01-04